Gene Silencing of TGFβRII Can Inhibit Glioblastoma Cell Growth

Document Type: Research Articles

Authors

1 Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.

2 Ischemic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran.

3 Gorgan Congenital Malformations Research Center, Golestan University of Medical Sciences, Gorgan, Iran.

4 Mobility Impairment Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.

5 Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

6 Department of Physiology, Babol University of Medical Sciences, Babol, Iran.

7 Department of Biostatistics and Epidemiology, Babol University of Medical Sciences, Babol, Iran.

Abstract

Objective: Glioblastoma (GBM) is the most malignant and aggressive type of glioma, associated with a high rate
of mortality. The transforming growth factor-β receptor II (TGFβ RII) is involved in glioma initiation and progression.
On the other hand, TGFβ RII silencing is critical to the inhibition of GBM. Therefore, we aimed to determine the
effects of specific TGFβ RII siRNA on the survival of U-373MG cells. Methods: TGFβ RII siRNA was transfected,
and qRT-PCR was performed to examine TGFβ RII mRNA expression. Cell survival was determined using colorimetric
MTT assay, and platelet-derived growth factor-BB (PDGF-BB) level was measured in the culture supernatant using
ELISA assay. Result: Our findings indicated that specific siRNAs could dose-dependently suppress TGFβ RII mRNA
expression after 48 hours. In addition, treatment with TGFβ RII siRNA significantly reduced tumor cell survival and
decreased the amount of PDGF-BB protein in the cell culture supernatant. Conclusion: Our results suggest that TGFβ
RII silencing can be a promising complementary treatment for glioma.

Keywords

Main Subjects